MetLife Investment Advisors LLC Buys New Stake in Ironwood Pharmaceuticals (IRWD)

MetLife Investment Advisors LLC bought a new stake in shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) during the 4th quarter, Holdings Channel reports. The firm bought 63,682 shares of the biotechnology company’s stock, valued at approximately $955,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Brown Capital Management LLC lifted its position in Ironwood Pharmaceuticals by 0.7% during the fourth quarter. Brown Capital Management LLC now owns 6,263,825 shares of the biotechnology company’s stock valued at $93,895,000 after purchasing an additional 46,250 shares in the last quarter. Sarissa Capital Management LP purchased a new position in Ironwood Pharmaceuticals during the fourth quarter valued at $24,733,000. Senzar Asset Management LLC lifted its position in Ironwood Pharmaceuticals by 185.8% during the fourth quarter. Senzar Asset Management LLC now owns 1,448,800 shares of the biotechnology company’s stock valued at $21,718,000 after purchasing an additional 941,800 shares in the last quarter. New York State Common Retirement Fund lifted its position in Ironwood Pharmaceuticals by 3.5% during the third quarter. New York State Common Retirement Fund now owns 1,404,659 shares of the biotechnology company’s stock valued at $22,151,000 after purchasing an additional 47,675 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Ironwood Pharmaceuticals by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 1,239,906 shares of the biotechnology company’s stock valued at $18,586,000 after acquiring an additional 30,901 shares in the last quarter.

In other news, insider Mark G. Currie sold 60,000 shares of Ironwood Pharmaceuticals stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $15.45, for a total value of $927,000.00. Following the sale, the insider now directly owns 835,000 shares of the company’s stock, valued at $12,900,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Gina Consylman sold 3,594 shares of Ironwood Pharmaceuticals stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $14.66, for a total value of $52,688.04. Following the completion of the sale, the chief financial officer now directly owns 59,125 shares in the company, valued at $866,772.50. The disclosure for this sale can be found here. Insiders sold 66,728 shares of company stock worth $1,024,732 over the last ninety days. Insiders own 7.63% of the company’s stock.



Shares of Ironwood Pharmaceuticals stock opened at $17.54 on Thursday. Ironwood Pharmaceuticals has a 52 week low of $12.89 and a 52 week high of $19.94. The stock has a market capitalization of $2,394.72, a PE ratio of -18.86 and a beta of 1.07. The company has a current ratio of 4.72, a quick ratio of 4.71 and a debt-to-equity ratio of 40.25.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. Ironwood Pharmaceuticals had a negative return on equity of 2,073.20% and a negative net margin of 39.20%. The business had revenue of $94.20 million for the quarter, compared to the consensus estimate of $88.86 million. During the same period in the previous year, the business earned ($0.12) earnings per share. The business’s revenue was up 7.7% on a year-over-year basis. equities research analysts anticipate that Ironwood Pharmaceuticals will post -0.46 EPS for the current fiscal year.

IRWD has been the topic of several research analyst reports. Bank of America downgraded Ironwood Pharmaceuticals from a “buy” rating to an “underperform” rating and lowered their price objective for the company from $20.00 to $15.00 in a research report on Friday, January 5th. BidaskClub downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 30th. Zacks Investment Research downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. ValuEngine downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, December 29th. Finally, Wells Fargo set a $18.00 price objective on Ironwood Pharmaceuticals and gave the company a “buy” rating in a research report on Monday. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company’s stock. Ironwood Pharmaceuticals has an average rating of “Hold” and an average price target of $17.14.

ILLEGAL ACTIVITY WARNING: “MetLife Investment Advisors LLC Buys New Stake in Ironwood Pharmaceuticals (IRWD)” was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://dakotafinancialnews.com/2018/04/12/metlife-investment-advisors-llc-buys-new-stake-in-ironwood-pharmaceuticals-irwd.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals (NASDAQ:IRWD).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply